Physician profile
Ronald A Simon
NPI 1255304622
$6,142.22
in general payments reported to CMS, 2019-2025
23 companies · $1,129 in 2025
The $1,129 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $2,244 · 2021: $126 · 2022: $596 · 2023: $725 · 2024: $669 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.90 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,662.92 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $589.25 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $444.80 | 2019-2025 | Dupixent |
| Genentech, INC. | $443.06 | 2019-2025 | Xolair |
| Genentech USA, INC. | $400.44 | 2019-2025 | Xolair |
| Pfizer INC. | $259.13 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $252.30 | 2020-2025 | Airsupra, Fasenra, Tezspire |
| Grifols USA, LLC | $196.32 | 2022-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $179.14 | 2019-2025 | |
| Optinose US, INC. | $129.01 | 2019-2024 | |
| Shire North American Group INC | $115.81 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $81.02 | 2025 | Dupixent |
| Kaleo, INC. | $60.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.37 | 2019-2020 | |
| Csl Behring | $54.88 | 2019-2025 | Hizentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $46.60 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $39.28 | 2020-2024 | Cuvitru |
| Phadia US INC. | $32.73 | 2022 | |
| Blueprint Medicines Corporation | $26.57 | 2023 | Ayvakit |
| Incyte Corporation | $19.34 | 2025 | Opzelura |
| Hospira, INC. | $18.23 | 2022 | |
| Circassia INC. | $17.44 | 2019 | |
| Pharming Healthcare, INC. | $17.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.